A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC

被引：0

作者：

Han, B. ^{[1
]}

Chen, J. ^{[2
]}

Xie, Q. ^{[3
]}

Yao, W. ^{[4
]}

Shi, H. ^{[5
]}

Zhao, Y. ^{[6
]}

Song, W. ^{[7
]}

Jin, X. ^{[7
]}

Wang, Z. ^{[7
]}

Li, B. ^{[7
]}

Xia, Y. ^{[7
]}

Jiao, S. ^{[8
]}

机构：

[1] Shanghai Chest Hosp, Shanghai, Peoples R China

[2] Hunan Canc Hosp, Changsha, Peoples R China

[3] Fuzhou Pulm Hosp Fujian, Fuzhou, Peoples R China

[4] Jiangxi Prov Peoples Hosp, Nanchang, Jiangxi, Peoples R China

[5] First Hosp Gannan Med Univ, Ganzhou, Peoples R China

[6] Henan Canc Hosp, Zhengzhou, Peoples R China

[7] Akeso Biopharma Inc, Zhongshan, Peoples R China

[8] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

Penpulimab; Anlotinib; non-squamous non-small-cell lung cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P80.01

引用

页码：S650 / S650

页数：1

共 50 条

[1] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai
Qiu-Yan Chen
Dongping Chen
Chaosu Hu
Kunyu Yang
Jiyu Wen
Jingao Li
Ying-Rui Shi
Feng Jin
Ruilian Xu
Jianji Pan
Shenhong Qu
Ping Li
Chunhong Hu
Yi-Chun Liu
Yi Jiang
Xia He
Hung-Ming Wang
Wan-Teck Lim
Wangjun Liao
Xiaohui He
Xiaozhong Chen
Zhigang Liu
Xianglin Yuan
Qi Li
Xiaoyan Lin
Shanghua Jing
Yanju Chen
Yin Lu
Ching-Yun Hsieh
Muh-Hwa Yang
Chia-Jui Yen
Jens Samol
Hui Feng
Sheng Yao
Patricia Keegan
Rui-Hua Xu
[J]. Nature Medicine, 2021, 27 : 1536 - 1543
[2] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dongping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jingao
Shi, Ying-Rui
Jin, Feng
Xu, Ruilian
Pan, Jianji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Wan-Teck
Liao, Wangjun
He, Xiaohui
Chen, Xiaozhong
Liu, Zhigang
Yuan, Xianglin
Li, Qi
Lin, Xiaoyan
Jing, Shanghua
Chen, Yanju
Lu, Yin
Hsieh, Ching-Yun
Yang, Muh-Hwa
Yen, Chia-Jui
Samol, Jens
Feng, Hui
Yao, Sheng
Keegan, Patricia
Xu, Rui-Hua
[J]. NATURE MEDICINE, 2021, 27 (09) : 1536 - +
[3] Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.
Han, Baohui
Chen, Jianhua
Wang, Ziping
Li, Xingya
Wang, Lin
Wu, Lin
Xie, Qiang
Zhao, Yanqiu
Wang, Mengzhao
Lu, Junguo
Shi, Huaqiu
Ye, Feng
Mei, Xiaodong
Yao, Weirong
Yue, Lu
Jiang, Da
Zhao, Jian
Zhang, Shucai
Chen, Gongyan
Jiao, Shunchang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Lu, Shun
Wang, Jie
Yu, Yan
Yu, Xinmin
Hu, Yanping
Ai, Xinghao
Ma, Zhiyong
Li, Xingya
Zhuang, Wu
Liu, Yunpeng
Li, Weidong
Cui, Jiuwei
Wang, Dong
Liao, Wangjun
Zhou, Jianying
Wang, Zhehai
Sun, Yuping
Qiu, Xiusong
Gao, Jie
Bao, Yuanyuan
Liang, Liang
Wang, Mengzhao
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
[5] Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai
Qiu-Yan Chen
Dongping Chen
Chaosu Hu
Kunyu Yang
Jiyu Wen
Jingao Li
Ying-Rui Shi
Feng Jin
Ruilian Xu
Jianji Pan
Shenhong Qu
Ping Li
Chunhong Hu
Yi-Chun Liu
Yi Jiang
Xia He
Hung-Ming Wang
Wan-Teck Lim
Wangjun Liao
Xiaohui He
Xiaozhong Chen
Zhigang Liu
Xianglin Yuan
Qi Li
Xiaoyan Lin
Shanghua Jing
Yanju Chen
Yin Lu
Ching-Yun Hsieh
Muh-Hwa Yang
Chia-Jui Yen
Jens Samol
Hui Feng
Sheng Yao
Patricia Keegan
Rui-Hua Xu
[J]. Nature Medicine, 2022, 28 : 214 - 214
[6] Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
Andric, Zoran
Galffy, Gabriella
Dols, Manuel Cobo
Szima, Barna
Stojanovic, Goran
Petrovic, Marina
Felip, Enriqueta
Baz, David Vicente
Aix, Santiago Ponce
Juan-Vidal, Oscar
Szalai, Zsuzsanna
Losonczy, Gyorgy
Blanco, Antonio Calles
Bernabe, Reyes
Ledo, Gema Garcia
Hernandez, Andres Aguilar
Duecker, Klaus
Zhou, Dongli
Schroeder, Andreas
Guezel, Guelseren
Ciardiello, Fortunato
[J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
[7] Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.
Wang, Wei
Lin, Shuimiao
Wang, Rong
Wu, Dehua
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS482 - TPS482
[8] Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Piccirillo, Maria Carmela
Bonanno, Laura
Garassino, Marina Chiara
Esposito, Giovanna
Dazzi, Claudio
Cavanna, Luigi
Burgio, Marco Angelo
Rosetti, Francesco
Rizzato, Simona
Morgillo, Floriana
Cinieri, Saverio
Veccia, Antonello
Papi, Maximilan
Tonini, Giuseppe
Gebbia, Vittorio
Ricciardi, Serena
Pozzessere, Daniele
Ferro, Alessandra
Proto, Claudia
Costanzo, Raffaele
D'Arcangelo, Manolo
Proietto, Manuela
Gargiulo, Piera
Di Liello, Raimondo
Arenare, Laura
De Marinis, Filippo
Crino, Lucio
Ciardiello, Fortunato
Normanno, Nicola
Gallo, Ciro
Perrone, Francesco
Gridelli, Cesare
Morabito, Alessandro
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1086 - 1097
[9] Effectiveness of docetaxel and cisplatin combination as first-line chemotherapy in advanced NSCLC
Behera, D
Aggarwal, A
Gupta, D
Jindal, S
Aggarwal, R
Sharma, S
Kapoor, R
[J]. LUNG CANCER, 2005, 49 : S389 - S389
[10] Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints
Han, B.
Chu, T.
Zhong, R.
Zhong, H.
Zhang, B.
Zhang, W.
Shi, C.
Qian, J.
Zhang, Y.
Chang, Q.
Zhang, X.
Dong, Y.
Teng, J.
Gao, Z.
Qiang, H.
Nie, W.
Zhao, Y.
Han, Y.
Chen, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S119 - S119

← 1 2 3 4 5 →